Royal Bank Of Canada Theseus Pharmaceuticals, Inc. Transaction History

Royal Bank Of Canada

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$2.12 - $4.18 $2,418 - $4,769	-1,141 Reduced 16.89%	5,615 $22,000
Q3 2023 Nov 14, 2023	BUY	$2.66 - $10.04 $12,353 - $46,625	4,644 Added 219.89%	6,756 $18,000
Q2 2023 Aug 14, 2023	BUY	$7.28 - $11.82 $7,884 - $12,801	1,083 Added 105.25%	2,112 $19,000
Q1 2023 May 15, 2023	SELL	$5.21 - $14.05 $9,836 - $26,526	-1,888 Reduced 64.72%	1,029 $9,000
Q4 2022 Feb 14, 2023	BUY	$4.69 - $8.36 $12,714 - $22,663	2,711 Added 1316.02%	2,917 $14,000
Q3 2022 Nov 14, 2022	BUY	$5.7 - $8.68 $627 - $954	110 Added 114.58%	206 $1,000
Q2 2022 Aug 15, 2022	SELL	$5.04 - $14.05 $3,079 - $8,584	-611 Reduced 86.42%	96 $1,000
Q1 2022 May 16, 2022	SELL	$8.75 - $14.51 $13,781 - $22,853	-1,575 Reduced 69.02%	707 $8,000
Q4 2021 Feb 14, 2022	BUY	$8.98 - $20.09 $20,492 - $45,845	2,282 New	2,282 $29,000

1.03M

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.